派司奴单抗和依多萨林治疗遗传性转甲状腺素蛋白淀粉样变性的效果和价值。
The Effectiveness and Value of Patisiran and Inotersen for Hereditary Transthyretin Amyloidosis.
机构信息
1 Institute for Clinical and Economic Review, Boston, Massachusetts.
2 Boston University School of Medicine, Boston, Massachusetts.
出版信息
J Manag Care Spec Pharm. 2019 Jan;25(1):10-15. doi: 10.18553/jmcp.2019.25.1.010.
Funding for this summary was contributed by the Laura and John Arnold Foundation, Blue Shield of California, and California Health Care Foundation to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, AHIP, Anthem, Blue Shield of California, CVS Caremark, Express Scripts, Harvard Pilgrim Health Care, Cambia Health Solutions, United Healthcare, Kaiser Permanente, Premera Blue Cross, AstraZeneca, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, National Pharmaceutical Council, Prime Therapeutics, Sanofi, Spark Therapeutics, Health Care Service Corporation, Editas, Alnylam, Regeneron, Mallinkrodt, Biogen, HealthPartners, and Novartis. Mickle, Dreitlein, and Pearson are ICER employees. Lasser, Cipriano, and Hoch have nothing to disclose.
本摘要的资金由 Laura and John Arnold 基金会、加州蓝盾和加州医疗保健基金会提供给临床与经济评价研究所（ICER），这是一个独立的组织，负责评估医疗保健干预措施的价值证据。ICER 的年度政策峰会由 Aetna、AHIP、Anthem、加州蓝盾、CVS Caremark、Express Scripts、Harvard Pilgrim Health Care、Cambia Health Solutions、United Healthcare、Kaiser Permanente、Premera Blue Cross、AstraZeneca、Genentech、GlaxoSmithKline、Johnson & Johnson、Merck、National Pharmaceutical Council、Prime Therapeutics、Sanofi、Spark Therapeutics、Health Care Service Corporation、Editas、Alnylam、Regeneron、Mallinkrodt、Biogen、HealthPartners 和 Novartis 等公司的会费支持。Mickle、Dreitlein 和 Pearson 是 ICER 的员工。Lasser、Cipriano 和 Hoch 没有要披露的信息。
Zotero 插件